Ovarian Cancer Clinical Trial

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Summary

This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of PF-07263689, either alone or in combination with sasanlimab (an investigational anti-programmed cell death protein 1 [PD-1] antibody), in patients with selected locally advanced or metastatic solid tumors who have exhausted all available standard of care therapies available to them.

The study consists of 2 parts: Part 1 dose escalation for PF-07263689 monotherapy (Part 1A) and in combination with sasanlimab (Part 1B), followed by Part 2 dose expansion for the combination therapy.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histological or cytological diagnosis of locally advanced or metastatic solid tumors known to have approved therapies using immune checkpoint inhibitors or anti-vascular endothelial growth factor agents
Have exhausted (or refuse) all available standard of care therapy (e.g., including anti-PD1/programmed death ligand 1 [PDL1] if applicable) or for whom no standard therapy is available for their tumor type
Patients with prior anti-PD1/PDL1 must have documentation of primary or secondary resistance to last prior anti-PD1/PDL1 therapy according to Immunotherapy Resistance Committee (SITC) (Kluger et al, 2020)
Have at least 1 measurable lesion by RECIST 1.1 that has not been previously irradiated (for Part 2 only)
Have recently obtained archival tumor tissue sample available, or undergo de novo tumor biopsy
Eastern Cooperative Oncology Group (ECOG) PS 0-1
Adequate hematologic, renal, and liver functions
Dose Escalation (Part 1A and 1B): Any advanced or metastatic solid tumor fulfilling other relevant eligibility criteria.
Dose Expansion (Part 2): Tumor specific cohorts (NSCLC, RCC, melanoma, MSS CRC) must have received prior approved therapies (Part 2)

Exclusion Criteria:

Other active malignancy
Recent major surgery
Systemic anticancer therapy and chemotherapy within protocol-defined washout period
Known or suspected hypersensitivity to prior treatment with any vaccinia oncolytic, pox virus, or antiviral agents within the past 10 years
Current or history of myocarditis or congestive heart failure (New York Heart Association [NYHA] III-IV); unstable angina; or serious uncontrolled arrhythmia or recent myocardial infarction
Active or history of interstitial lung disease (ILD)/pneumonitis
Patients requiring chronic systemic immunosuppressants
History of severe immune mediated side effect that was considered related to prior immune modulatory therapy and requiring immunosuppressive therapy
Known symptomatic brain metastases requiring steroids
History of or ongoing severe inflammatory skin conditions or severe eczema having required medical treatment
Any prior or planned organ transplant
Presence of any open, active wound requiring treatment

Study is for people with:

Ovarian Cancer

Phase:

Phase 1

Estimated Enrollment:

10

Study ID:

NCT05061537

Recruitment Status:

Active, not recruiting

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

City of Hope
Duarte California, 91010, United States
The University of Louisville, James Graham Brown Cancer Center
Louisville Kentucky, 40202, United States
UMC Health Care Outpatient Center (For Imaging)
Louisville Kentucky, 40202, United States
University of Louisville Hospital
Louisville Kentucky, 40202, United States
Columbia University Medical Center
New York New York, 10032, United States
CUMC Research Pharmacy
New York New York, 10032, United States

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 1

Estimated Enrollment:

10

Study ID:

NCT05061537

Recruitment Status:

Active, not recruiting

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.